QNZ (EVP4593): Potent Quinazoline NF-κB Inhibitor for Inflammation and Neurodegeneration

Executive Summary: QNZ (EVP4593) is a small-molecule quinazoline derivative that potently inhibits the NF-κB signaling pathway, with an IC50 of 11 nM in human Jurkat T cells (APExBIO). It suppresses PMA/PHA-induced NF-κB activation and TNF-α production at an IC50 of 7 nM. QNZ demonstrates significant anti-inflammatory efficacy in rodent models, reducing edema formation. The compound is effective in Drosophila models of Huntington’s disease, slowing motor decline without toxicity (Yang et al., 2025). QNZ is recommended for research on NF-κB pathway modulation, inflammation, and neurodegeneration, with validated protocols for solubility and storage.

Biological Rationale

The NF-κB signaling pathway is a central regulator of inflammation, immune responses, and cell survival. Aberrant activation of NF-κB is implicated in various inflammatory diseases, cancers, and neurodegenerative disorders, including Huntington’s disease (HD) (Yang et al., 2025). Targeted inhibition of NF-κB transcriptional activation can attenuate pathological inflammation and modulate disease progression. QNZ (EVP4593) is a small-molecule inhibitor designed to specifically suppress NF-κB pathway activation, providing a valuable tool for dissecting molecular mechanisms underlying inflammatory and neurodegenerative diseases (APExBIO).

Mechanism of Action of QNZ (EVP4593)

QNZ (EVP4593) is a quinazoline derivative identified via luciferase reporter gene assays. It directly inhibits NF-κB transcriptional activation by impeding nuclear translocation and DNA binding of NF-κB subunits. In human Jurkat T cells, QNZ blocks PMA/PHA-induced NF-κB activation, achieving an IC50 of 11 nM. In the same model, QNZ suppresses TNF-α production with an IC50 of 7 nM, indicating potent anti-inflammatory activity under immunostimulatory conditions (APExBIO).

QNZ also affects calcium signaling: in neuronal cultures, treatment at 300 nM attenuates store-operated calcium entry (SOC) influx, which is relevant to HD pathology. By modulating these signaling pathways, QNZ exerts both anti-inflammatory and neuroprotective effects (see Advanced NF-κB Inhibition for Neurodegeneration—this article extends the mechanistic detail and translational benchmark data beyond the linked review).

Evidence & Benchmarks

• QNZ (EVP4593) inhibits NF-κB activation with an IC50 of 11 nM in human Jurkat T cells (APExBIO product documentation, link).
• Suppresses PMA/PHA-induced TNF-α production (IC50 = 7 nM) in the same cellular context (APExBIO, link).
• Reduces edema formation in a rat carrageenin-induced paw edema model, demonstrating robust anti-inflammatory action (APExBIO).
• In Drosophila HD transgenic models, QNZ treatment slows progressive motor decline and has no observed toxicity (Yang et al., 2025).
• QNZ is insoluble in water, but dissolves in ethanol (≥10.06 mg/mL) or DMSO (≥15.05 mg/mL) under ultrasonic assistance at 37°C (APExBIO).
• Stock solutions are stable at -20°C for short-term use; long-term solution storage is not recommended due to potential degradation (APExBIO).

For a discussion of practical laboratory workflows and scenario-driven protocol optimization, see Scenario-Driven Best Practices for Reliable NF-κB Pathway Research—this article provides extended troubleshooting and optimization guidance not detailed here.

Applications, Limits & Misconceptions

QNZ (EVP4593) is employed in diverse research contexts:

• Characterization of NF-κB pathway regulation in immune, inflammatory, and neurodegenerative disease models.
• Assessment of anti-inflammatory drug candidates in cellular and animal systems.
• Investigation of calcium signaling in neuronal cultures, especially SOC influx relevant to Huntington’s disease (Potent Quinazoline NF-κB Inhibitor for Inflammation—this article adds recent neurodegenerative application data and practical workflow advice).
• Study of fibrosis, infection, and tissue remodeling processes where NF-κB plays a regulatory role (Yang et al., 2025).

Common Pitfalls or Misconceptions

• QNZ is not soluble in water: Use ethanol or DMSO for stock solutions; ultrasonic assistance and warming to 37°C are required for optimal solubility (APExBIO).
• Long-term storage in solution is not recommended: Prepare fresh stocks for each experimental run.
• QNZ does not inhibit all inflammatory pathways: Its action is specific to NF-κB and related signaling.
• Not a clinical therapy: QNZ is for research use only and is not approved for therapeutic application.
• Concentration-dependent effects: Dosing above recommended levels (e.g., >1 μM) may induce off-target effects or cytotoxicity; always titrate per protocol.

Workflow Integration & Parameters

For reliable NF-κB inhibition in vitro, dissolve QNZ at ≥10.06 mg/mL in ethanol or ≥15.05 mg/mL in DMSO using ultrasonic bath and warming (37°C) (APExBIO). Prepare aliquots and store at -20°C; avoid repeated freeze-thaw cycles. In neuronal cultures, 300 nM is a benchmark concentration to attenuate SOC influx, relevant for Huntington’s disease models. For anti-inflammatory studies in animal models, dosing and administration routes should be adapted based on species and study design. Documentation of solvent, temperature, and incubation times is crucial for reproducibility (Data-Driven Solutions for Reliable NF-κB Pathway Inhibition—this article offers additional workflow and assay optimization advice).

Conclusion & Outlook

QNZ (EVP4593) is a benchmark tool for precise NF-κB signaling pathway modulation in inflammation and neurodegenerative research, supplied by APExBIO. Its nanomolar potency, documented anti-inflammatory effects, and established role in Huntington’s disease models support its continued adoption in preclinical workflows. Future studies may further define optimal protocols for emerging disease models and clarify any off-target actions. For ordering details and up-to-date technical specifications, consult the QNZ (EVP4593) product page.